The first company to develop a singlicate testing qPCR assay for BCR-ABL with a sensitivity level that empowers physicians to monitor Complete Molecular Response in patients with CML*. The MR4.7 sensitivity attained, illustrates Asuragen’s ability to combine advanced proprietary bioinformatics with unique qPCR chemistry expertise to produce an assay that enables a significant change in clinical practice.
*CE-IVD and US export only.
Learn more about our qPCR assay for BCR-ABL:
QuantideX qPCR BCR-ABL IS CE-IVD Kit